We use cookies for a better user experience. Read our Privacy Policy

I Agree

Liposome Drug Delivery Market

Liposome Drug Delivery Market (Product: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and Others; Technology: Stealth Liposome Technology, Non-PEGylated Liposome Technology, and DepoFoam Liposome Technology; and Application: Fungal Diseases, Pain Management, Cancer Therapy, Viral Vaccines, and Photodynamic Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Special Nanomaterials and Liposomes Hold Potential as Antiviral Agents against Coronavirus

The COVID-19 (coronavirus) has exposed the vulnerabilities of healthcare facilities. Due to the increasing number of COVID-19 patients, especially in the U.S. and European countries, research institutes are pressurized to accelerate their R&D activities to develop drugs and vaccines for the treatment of coronavirus. Thus, companies in the liposome drug delivery market are capitalizing on this opportunity to increase their research in nanomaterials such as nanospheres, liposomes, and nanoparticles that are effective antiviral agents. Liposome drug delivery is being leveraged with increased in vivo and in vitro drug activities for routine clinical practices.

Companies in the liposome drug delivery market are increasing their focus on drug delivery nanosystems involving major antiviral classes and their transport across specific barriers at cellular and intracellular levels. Thus, liposomes hold promising potentials in ongoing research studies being carried out by healthcare companies for the treatment of coronavirus.

liposome drug delivery market infographic

To know the scope of our report Get a Sample on Liposome Drug Delivery Market 

Liposome Drug Delivery Transitions from Conventional Vesicles to Second Generation Liposomes

New strategies in surface modification of liposomes are generating incremental opportunities for pharmaceutical companies. The liposome drug delivery is being highly publicized as a useful biocompatible tool for the vehiculation and delivery of lipophilic, hydrophilic, and ampiphilic compounds. However, high toxicity and resistance in high doses are some of the limitations faced by companies in the liposome drug delivery market. Hence, companies are transitioning from simple conventional vesicles to second-generation liposomes by attuning the lipid composition and surface with different ligands.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies are focusing on surface chemistry of the liposome technology. Increased research in liposome technology are contributing toward a robust CAGR of ~9% for the liposome drug delivery market. PEGylated liposomes are gaining popularity for possessing higher drug loading capacity. Novel drugs such as the CPX-1 encapsulated in liposomes are beneficial for increased disease control in patients suffering from colorectal cancer. As such, the revenue of cancer therapy application segment is projected for aggressive growth during the forecast period.

New Lipid Compositions Optimize Stability and Drug Vehiculization Capabilities of Liposomes

Liposomes are gaining widespread acceptance as Nano-carriers for diverse pharmaceutical applications. Compositions of phospholipids and cholesterol are becoming increasingly useful in liposome drug delivery. On the other hand, nanotechnology is optimizing liposome drug delivery. Hence, pharmaceutical companies are exploring alternative compositions with cholesterol and new techniques such as nanotechnology to enhance the stability and drug release profiles. They are using liposomes to its full potential for the generation of extracellular vesicles by targeted cells.

Companies in the liposome drug delivery market are increasing their R&D activities to unlock new lipid compositions and strategies that optimize the stability and drug vehiculization capabilities of liposomes. Such experiments are instrumental for innovative liposome fabrication. This explains why the liposome drug delivery market is expected to experience favorable Y-o-Y growth, owing to an estimated revenue of ~US$ 8 Bn by the end of 2027. Thus, innovative designs in liposomal architectures are proving beneficial for improved in vivo and in vitro drug activities.

Liposomes Gain Popularity for Enhancing Circulation Time of Hydrophobic Substances

Therapeutic efficacy of PEGylated liposomal Doxorubicin is being leveraged with improved liposomal formulations of galbanic acid (Gba) in the liposome drug delivery market. Galbanic acid is a sesquiterpene coumarin possessing strong antiangiogenic activity, resulting in promising potential as an anti-cancer agent. However, galbanic acid poses limitations in water solubility, thus hampering its clinical applications. Hence, companies in the market for liposome drug delivery are increasing the applicability of PEGylated liposomal Gba produced through the thin film hydration plus extrusion method to overcome limitations of poor Gba solubility.

Present chemotherapeutic agents in cancer chemotherapy are accompanied with several side effects. Hence, companies in the liposome drug delivery market are increasing their efficacy in PEGylated liposomal Gba to minimize side effects in patients. As such, liposomes are acquiring popularity to enhance circulation time and reduce the systemic toxicity of hydrophobic substances such as Gba to leverage their therapeutic efficacy for drugs in the market of liposome drug delivery.

liposome drug delivery market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

Liposomes are being highly publicized as potential antiviral agents instrumental in reducing social impact and economic burden caused due to the COVID-19 outbreak. Companies in the liposome drug delivery market are gaining expertise in the formulation of advanced liposomes possessing greater solubility and long circulating time to improve drug release profiles.

Surface chemistry of liposome technology has enabled liposomes to be further liganded with vitamins, carbohydrates, and peptides, among others. However, maintaining physical properties of liposomal formulations poses as a challenge for market players. Hence, companies should refer the NRC’s (National Research Council) certified reference material program to comply with industry standards and maintain physical characteristics of liposomal formulations.

Liposome Drug Delivery Market: Overview

  • The global liposome drug delivery market was valued at US$ 3.6 Bn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027. Liposomes are considered the novel drug delivery systems, which are defined as vesicular structures consisting of bilayers formed spontaneously when phospholipids are dispersed in water. Liposomes aid in delivering drugs by the process of diffusion rather than by direct cell fusion.
  • The global liposome drug delivery market is driven by rise in prevalence of cancer, which is primarily treated with liposome encapsulated drugs, increase in applications of liposomes as drug delivery systems, its advantages, technological advances, and strong pipeline of drugs
  • Advantages offered by liposome drug delivery, including the unique ability to entrap both hydrophilic and lipophilic compounds and enabling a diverse range of drugs to be encapsulated by these vesicles, contribute to the growth of the global market
  • Applications of liposomes in drug delivery can be segregated into diagnostic and therapeutic. These applications include anti-fungal, anti-cancer, and anti-inflammatory drugs, in addition to therapeutic gene delivery. Major drugs formulated by employing liposome drug delivery include Doxil, AmBisome, and DepoDur. Surge in applications of liposomes as drug delivery systems contributes to the growth of the global liposome drug delivery market.

Liposome Drug Delivery Market: Segmentation

  • The global liposome drug delivery market has been segmented based on product, technology, application, and region
  • In terms of product, the global liposome drug delivery market has been categorized into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others
  • Based on technology, the global liposome drug delivery market has been classified into stealth liposome technology, non-PEGylated liposome technology, and DepoFoam liposome technology
  • In terms of application, the global liposome drug delivery market has been divided into fungal diseases, cancer therapy, viral vaccines, pain management, and photodynamic therapy. The cancer therapy segment dominated the market in 2018 and the trend is anticipated to continue during the forecast period. This can be attributed to rise in prevalence of cancer and strong pipeline of drugs focused on offering treatment for various types of cancer.

Liposome Drug Delivery Market: Regional Segmentation

  • In terms of region, the global liposome drug delivery market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global liposome drug delivery market in 2018 and the trend is expected to continue during the forecast period
  • The liposome drug delivery market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. Growth of the market in the region can be attributed to increase in number of patients suffering from chronic diseases and focus of leading players on strengthening presence in emerging markets.

Liposome Drug Delivery Market: Major Players

  • Key players operating in the global liposome drug delivery market are 
    • Spectrum Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
    • Gilead Sciences, Inc.
    • Celsion Corporation
    • Ipsen Pharma
    • Pacira BioSciences, Inc.
    • Luye Pharma Group
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Johnson & Johnson
  • These players focus on adopting inorganic growth strategies and product launches to strengthen their product portfolio. These players also emphasize on enhancement of technological platforms for the development of liposome drugs. For instance, Celsion Corporation focuses on the development of cancer therapies based on its Lysolipid Thermally Sensitive Liposomes (LTSL), which is a heat-sensitive liposomal formulation. The other technology platforms include TheraPlas, a non-viral delivery system for therapeutic plasmids. The third technology platform is TheraSilence, which aids in delivering synthetically generated inhibitory RNA (RNAi) to regulate protein expression in target cells.

Liposome Drug Delivery Market – Segmentation

Product

Liposomal Doxorubicin

Liposomal Paclitaxel

Liposomal Amphotericin B

Others

Technology

Stealth Liposome Technology

Non-PEGylated Liposome Technology

DepoFoam Liposome Technology

Application

Fungal Diseases

Cancer Therapy

Pain Management

Viral Vaccines

Photodynamic Therapy

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

 1. Preface

     1.1. Market Definition and Scope

     1.2. Market Segmentation

     1.3. Key Research Objectives

     1.4. Research Highlights

 2. Assumptions and Acronyms

 3. Research Methodology

 4. Executive Summary: Global Liposome Drug Delivery Market

 5. Market Overview

     5.1. Definition

     5.2. Market Indicators

     5.3. Market Dynamics

         5.3.1. Drivers

         5.3.2. Restraints

         5.3.3. Opportunities

     5.4. Global Liposome Drug Delivery Market Revenue (US$ Mn) Forecast 2017–2027

     5.5. Global Liposome Drug Delivery Market Outlook

 6. Key Insights

     6.1. Pipeline Analysis

     6.2. Clinically Marketed Liposome Drugs

     6.3. Regulatory Scenario Assessment

 7. Global Liposome Drug Delivery Market Analysis and Forecast, by Product 

     7.1. Introduction 

     7.2. Global Liposome Drug Delivery Market Value Share Analysis, by Product

     7.3. Global Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         7.3.1. Liposomal Doxorubicin

         7.3.2. Liposomal Paclitaxel

         7.3.3. Liposomal Amphotericin B

         7.3.4. Others

     7.4.  Global Liposome Drug Delivery Market Attractiveness Analysis, by Product 

 8. Global Liposome Drug Delivery Market Analysis and Forecast, by Technology

     8.1. Introduction 

     8.2. Global Liposome Drug Delivery Market Value Share Analysis, by Technology

     8.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         8.3.1. Stealth Liposome Technology

         8.3.2. Non-PEGylated Liposome Technology

         8.3.3. DepoFoam Liposome Technology

     8.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology

 9. Global Liposome Drug Delivery Market Analysis and Forecast, by Application

     9.1. Introduction 

     9.2. Global Liposome Drug Delivery Market Value Share Analysis, by Application

     9.3. Global Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         9.3.1. Fungal Diseases

         9.3.2. Pain Management

         9.3.3. Cancer Therapy

         9.3.4. Viral Vaccines

         9.3.5. Photodynamic Therapy

     9.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology

 10. Global Liposome Drug Delivery Market Analysis and Forecast, by Region 

     10.1. Regional Outlook

     10.2. Introduction

     10.3. Global Liposome Drug Delivery Market Value Forecast, by Region

         10.3.1. North America

         10.3.2. Europe 

         10.3.3. Asia Pacific

         10.3.4. Latin America 

         10.3.5. Middle East & Africa

     10.4. Global Liposome Drug Delivery Market Attractiveness Analysis, by Region

 11. North America Liposome Drug Delivery Market Analysis and Forecast

     11.1.  Key Findings

     11.2.  North America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         11.2.1. Liposomal Doxorubicin

         11.2.2. Liposomal Paclitaxel

         11.2.3. Liposomal Amphotericin B

         11.2.4. Others 

     11.3. North America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         11.3.1. Stealth Liposome Technology

         11.3.2. Non-PEGylated Liposome Technology

         11.3.3. DepoFoam Liposome Technology

     11.4. North America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

         11.4.1. Fungal Diseases

         11.4.2. Pain Management

         11.4.3. Cancer Therapy

         11.4.4. Viral Vaccines

         11.4.5. Photodynamic Therapy

     11.5. North America Liposome Drug Delivery Market Value Forecast, by Country, 2017–2027

         11.5.1. U.S.

         11.5.2. Canada

     11.6. North America Liposome Drug Delivery Market Attractiveness Analysis

         11.6.1. By Product

         11.6.2. By Technology

         11.6.3. By Application

         11.6.4. By Country

 12. Europe Liposome Drug Delivery Market Analysis and Forecast

     12.1.  Key Findings

     12.2.  Europe Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         12.2.1. Liposomal Doxorubicin

         12.2.2. Liposomal Paclitaxel

         12.2.3. Liposomal Amphotericin B

         12.2.4. Others 

     12.3. Europe Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         12.3.1. Stealth Liposome Technology

         12.3.2. Non-PEGylated Liposome Technology

         12.3.3. DepoFoam Liposome Technology

     12.4. Europe Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

         12.4.1. Fungal Diseases

         12.4.2. Pain Management

         12.4.3. Cancer Therapy

         12.4.4. Viral Vaccines

         12.4.5. Photodynamic Therapy

     12.5. Europe Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

         12.5.1. U.K.

         12.5.2. Germany

         12.5.3. France

         12.5.4. Italy 

         12.5.5. Spain

         12.5.6. Rest of Europe

     12.6. Europe Liposome Drug Delivery Market Attractiveness Analysis

         12.6.1. By Product

         12.6.2. By Technology

         12.6.3. By Application

         12.6.4. By Country/Sub-region

 13. Asia Pacific Liposome Drug Delivery Market Analysis and Forecast

     13.1.  Key Findings

     13.2.  Asia Pacific Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         13.2.1. Liposomal Doxorubicin

         13.2.2. Liposomal Paclitaxel

         13.2.3. Liposomal Amphotericin B

         13.2.4. Others 

     13.3. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         13.3.1. Stealth Liposome Technology

         13.3.2. Non-PEGylated Liposome Technology

         13.3.3. DepoFoam Liposome Technology

     13.4. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

         13.4.1. Fungal Diseases

         13.4.2. Pain Management

         13.4.3. Cancer Therapy

         13.4.4. Viral Vaccines

         13.4.5. Photodynamic Therapy

     13.5. Asia Pacific Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

         13.5.1. China

         13.5.2. India

         13.5.3. Japan

         13.5.4. Australia & New Zealand 

         13.5.5. Rest of Asia Pacific 

     13.6. Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis

         13.6.1. By Product

         13.6.2. By Technology

         13.6.3. By Application

         13.6.4. By Country/Sub-region

 14. Latin America Liposome Drug Delivery Market Analysis and Forecast

     14.1.  Key Findings

     14.2.  Latin America Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         14.2.1. Liposomal Doxorubicin

         14.2.2. Liposomal Paclitaxel

         14.2.3. Liposomal Amphotericin B

         14.2.4. Others 

     14.3. Latin America Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         14.3.1. Stealth Liposome Technology

         14.3.2. Non-PEGylated Liposome Technology

         14.3.3. DepoFoam Liposome Technology

     14.4. Latin America Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

         14.4.1. Fungal Diseases

         14.4.2. Pain Management

         14.4.3. Cancer Therapy

         14.4.4. Viral Vaccines

         14.4.5. Photodynamic Therapy

     14.5. Latin America Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

         14.5.1. Brazil

         14.5.2. Mexico

         14.5.3. Rest of Latin America 

     14.6. Latin America Liposome Drug Delivery Market Attractiveness Analysis

         14.6.1. By Product

         14.6.2. By Technology

         14.6.3. By Application

         14.6.4. By Country/Sub-region

 15. Middle East & Africa Liposome Drug Delivery Market Analysis and Forecast

     15.1.  Key Findings

     15.2.  Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Product, 2017–2027

         15.2.1. Liposomal Doxorubicin

         15.2.2. Liposomal Paclitaxel

         15.2.3. Liposomal Amphotericin B

         15.2.4. Others 

     15.3. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Technology, 2017–2027

         15.3.1. Stealth Liposome Technology

         15.3.2. Non-PEGylated Liposome Technology

         15.3.3. DepoFoam Liposome Technology

     15.4. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Application, 2017–2027

         15.4.1. Fungal Diseases

         15.4.2. Pain Management

         15.4.3. Cancer Therapy

         15.4.4. Viral Vaccines

         15.4.5. Photodynamic Therapy

     15.5. Middle East & Africa Liposome Drug Delivery Market Value Forecast, by Country/Sub-region, 2017–2027

         15.5.1. GCC Countries

         15.5.2. South Africa

         15.5.3. Rest of Middle East & Africa 

     15.6. Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis

         15.6.1. By Product

         15.6.2. By Technology

         15.6.3. By Application

         15.6.4. By Country/Sub-region

 16. Competition Landscape

     16.1.  Company Profiles

         16.1.1. Spectrum Pharmaceuticals, Inc. 

             16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.1.2. Financial Overview

             16.1.1.3. Product Portfolio

             16.1.1.4. Strategic Overview

             16.1.1.5. SWOT Analysis

         16.1.2. Astellas Pharma Inc. 

             16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.2.2. Financial Overview

             16.1.2.3. Product Portfolio

             16.1.2.4. Strategic Overview

             16.1.2.5. SWOT Analysis

         16.1.3. Gilead Sciences, Inc. 

             16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.3.2. Financial Overview

             16.1.3.3. Product Portfolio

             16.1.3.4. Strategic Overview

             16.1.3.5. SWOT Analysis

         16.1.4. Celsion Corporation

             16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.4.2. Financial Overview

             16.1.4.3. Product Portfolio

             16.1.4.4. Strategic Overview

             16.1.4.5. SWOT Analysis

         16.1.5. Ipsen Pharma

             16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.5.2. Financial Overview

             16.1.5.3. Product Portfolio

             16.1.5.4. Strategic Overview

             16.1.5.5. SWOT Analysis

         16.1.6. Pacira BioSciences, Inc.

             16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.6.2. Financial Overview

             16.1.6.3. Product Portfolio

             16.1.6.4. Strategic Overview

             16.1.6.5. SWOT Analysis

         16.1.7. Luye Pharma Group

             16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.7.2. Financial Overview

             16.1.7.3. Product Portfolio

             16.1.7.4. Strategic Overview

             16.1.7.5. SWOT Analysis

         16.1.8. Novartis AG

             16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.8.2. Financial Overview

             16.1.8.3. Product Portfolio

             16.1.8.4. Strategic Overview

             16.1.8.5. SWOT Analysis

         16.1.9. Takeda Pharmaceutical Company Limited

             16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.9.2. Financial Overview

             16.1.9.3. Product Portfolio

             16.1.9.4. Strategic Overview

             16.1.9.5. SWOT Analysis

         16.1.10. Johnson & Johnson

             16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

             16.1.10.2. Financial Overview

             16.1.10.3. Product Portfolio

             16.1.10.4. Strategic Overview

             16.1.10.5. SWOT Analysis

List of Tables

Table 01: Pipeline Analysis - Liposome Drug Delivery Systems

Table 02: Clinically Marketed Liposome Drugs

Table 03: Regulations - Principle difference between U.S., EU, and India 

Table 04: Regulatory Scenario Assessment - Administrative Requirements 

Table 05: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 06: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 07: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 08: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 09: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 11: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 12: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 13: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 14: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 15: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 16: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 17: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 19: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 20: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 21: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 23: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 24: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027

Table 25: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 26: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Product, 2017–2027

Table 27: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Technology, 2017–2027

Table 28: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast, by Application, 2017–2027 

List of Figures

Figure 01: Global Liposome Drug Delivery Market Snapshot

Figure 02: Global Liposome Drug Delivery Market Value (US$ Mn), by Region, 2018 and 2027

Figure 03: Therapeutic applications of liposomes in drug delivery 

Figure 04: Advantages of Liposome Drug Delivery System

Figure 05: Global Liposome Drug Delivery Market Value (US$ Mn) and Y-o-Y (%) Forecast, 2017–2027

Figure 06: Global Liposome Drug Delivery Market Value Share, by Product, 2019

Figure 07: Global Liposome Drug Delivery Market Value Share, by Technology, 2019

Figure 08: Global Liposome Drug Delivery Market Value Share, by Application, 2019

Figure 09: Global Liposome Drug Delivery Market Value Share, by Region, 2019

Figure 10: Regulatory Approval Process - U.S.

Figure 11: Regulatory Approval Process - Europe

Figure 12: Regulatory Approval Process - India

Figure 13: Global Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 14: Global Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 15: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Doxorubicin, 2017–2027

Figure 16: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Paclitaxel, 2017–2027

Figure 17: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liposomal Amphotericin B, 2017–2027

Figure 18: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 19: Global Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 20: Global Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 21: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stealth Liposome Technology, 2017–2027

Figure 22: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-PEGylated Liposome Technology, 2017–2027

Figure 23: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DepoFoam Liposome Technology, 2017–2027

Figure 24: Global Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 25: Global Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

Figure 26: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fungal Diseases, 2017–2027

Figure 27: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pain Management, 2017–2027

Figure 28: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Therapy, 2017–2027

Figure 29: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Viral Vaccines, 2017–2027

Figure 30: Global Liposome Drug Delivery Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Photodynamic Therapy, 2017–2027

Figure 31: Liposome Drug Delivery Market – Regional Outlook

Figure 32: Global Liposome Drug Delivery Market Value (US$ Mn) Forecast, 2017–2027

Figure 33: Global Liposome Drug Delivery Market Value Share Analysis, by Region, 2018 and 2027

Figure 34: Global Liposome Drug Delivery Market Attractiveness Analysis, by Region, 2019–2027

Figure 35: North America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 36: North America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 37: North America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 38: North America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 39: North America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 40: North America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 41: North America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 42: North America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 43: North America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

Figure 44: Europe Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 45: Europe Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 46: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 47: Europe Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 48: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 49: Europe Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 50: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 51: Europe Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 52: Europe Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

Figure 53: Asia Pacific Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 54: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 55: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 56: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 57: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 58: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 59: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 60: Asia Pacific Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 61: Asia Pacific Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

Figure 62: Latin America Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 63: Latin America Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 64: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 65: Latin America Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 66: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 67: Latin America Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 68: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 69: Latin America Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 70: Latin America Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027

Figure 71: Middle East & Africa Liposome Drug Delivery Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 72: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 73: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 74: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Product, 2018 and 2027

Figure 75: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Product, 2019–2027

Figure 76: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Technology, 2018 and 2027

Figure 77: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Technology, 2019–2027

Figure 78: Middle East & Africa Liposome Drug Delivery Market Value Share Analysis, by Application, 2018 and 2027

Figure 79: Middle East & Africa Liposome Drug Delivery Market Attractiveness Analysis, by Application, 2019–2027 

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved